Mario Lemieux Center for Blood Cancers
UPMC Hillman Cancer Center is part of the UPMC family.
To learn more or speak with a trial coordinator, please call 412-864-6600.
This Phase I trial studies the side effects and best dose of blinatumomab when given with nivolumab alone or nivolumab and ipilimumab in treating patients with poor-risk CD19+ precursor B-lymphoblastic leukemia that has come back after a period of improvement or has not responded to treatment. Monoclonal antibodies, such as blinatumomab, nivolumab and ipilimumab, may interfere with the ability of tumor cells to grow and spread.
Principal Investigator: Kathleen Dorritie, MD
Sponsor: National Cancer Institute
View eligibility criteria and the full trial at ClinicalTrials.gov.